Biogen (BIIB) EVP Chief Legal Officer granted 8,450 RSUs in equity award

Rhea-AI Filing Summary

ALEXANDER SUSAN H reported acquisition or exercise transactions in this Form 4 filing.

BIOGEN INC. reported that EVP and Chief Legal Officer Susan H. Alexander received a grant of 8,450 restricted stock units on February 13, 2026. These units represent a form of equity compensation rather than a cash transaction. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date, meaning the award is earned over time as continued service is provided.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ALEXANDER SUSAN H

Role EVP Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	8,450	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 8,450 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALEXANDER SUSAN H

(Last) (First) (Middle)

BIOGEN INC.

225 BINNEY STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	02/13/2026		A		8,450		(1)	02/13/2029	Common Stock	8,450	$0	8,450	D

Explanation of Responses:

1. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.

	/s/ Wendell Taylor, attorney-in-fact for Susan Alexander	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Biogen (BIIB) executive Susan H. Alexander report on this Form 4?

Susan H. Alexander reported receiving a grant of 8,450 restricted stock units from Biogen. The award is equity-based compensation, recorded at a price of $0.00 per unit, and will vest over several years rather than involving any immediate open-market stock purchase or sale.

How many restricted stock units did Biogen (BIIB) grant to Susan H. Alexander?

Biogen granted Susan H. Alexander 8,450 restricted stock units. This entire amount is reflected as acquired in a single transaction and represents the total derivative securities she held following the grant, aligning her compensation further with Biogen’s long-term share performance.

What is the vesting schedule of Susan H. Alexander’s Biogen (BIIB) restricted stock units?

The 8,450 restricted stock units vest in three equal yearly installments. Vesting begins on the first anniversary of the February 13, 2026 grant date, meaning the award becomes fully vested over three years, encouraging long-term retention and alignment with Biogen’s shareholders.

Did Susan H. Alexander buy or sell Biogen (BIIB) shares in this Form 4 filing?

The filing shows an acquisition of 8,450 restricted stock units as a grant, not an open-market buy or sell. The transaction price is listed as $0.00 per unit, indicating compensation rather than a cash purchase or sale of Biogen common stock.

How many Biogen (BIIB) restricted stock units does Susan H. Alexander hold after this grant?

After this grant, Susan H. Alexander is reported to hold 8,450 restricted stock units directly. This total matches the number of units granted in the transaction, reflecting her derivative equity position tied to Biogen’s share performance after the award.